香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 須予披露交易 (I)認購上海浦東發展銀行（海淀園支行）的結構性存款產品 (II)認購北京銀行（大興支行）的結構性存款產品 (III)認購北京銀行（方莊支行）的結構性存款產品 認購該等結構性存款產品 茲提述本公司日期為2025年3月31日的公告（「該公告」），內容有關（其中包括） 本公司認購北京銀行（方莊支行）及北京銀行（大興支行）的結構性存款產品。 誠如該公告所披露，於2025年3月31日，本公司訂立(i)北京銀行（大興支行）結構 性存款產品協議，同意使用其來自A股公開發行的臨時閒置募集資金認購北京 銀行（大興支行）的結構性存款產 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 須予披露交易 (I)認購上海浦東發展銀行（海淀園支行）的結構性存款產品 (II)認購北京銀行（大興支行）的結構性存款產品 (III)認購北京銀行（方莊支行）的結構性存款產品 認購該等結構性存款產品 茲提述本公司日期為2025年3月31日的公告（「該公告」），內容有關（其中包括） 本公司認購北京銀行（方莊支行）及北京銀行（大興支行）的結構性存款產品。 誠如該公告所披露，於2025年3月31日，本公司訂立(i)北京銀行（大興支行）結構 性存款產品協議，同意使用其來自A股公開發行的臨時閒置募集資金認購北京 銀行（大興支行）的結構性存款產 ...

Core Viewpoint - Spring Medical's stock has experienced significant fluctuations, with a year-to-date increase of 115.12% but a recent decline of 2.04% on November 11, 2023, indicating potential volatility in the market [1]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [1][2]. - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1]. Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a 213.21% increase compared to the previous year [2]. - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average number of tradable shares per shareholder decreased by 3.95% to 46,906 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed A, holding 2.9585 million shares and 2.8326 million shares, respectively [3].

Core Viewpoint - Spring Medical experienced a decline of 2.38% in stock price on November 7, with a trading volume of 83.6 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On November 7, Spring Medical had a financing buy-in amount of 7.79 million yuan and a financing repayment of 8.40 million yuan, resulting in a net financing outflow of 0.62 million yuan [1] - The total financing and securities balance as of November 7 was 47.58 million yuan, which represents 0.62% of the circulating market value and is above the 90th percentile level over the past year, indicating a high financing balance [1] - No shares were sold or repaid in the securities lending market on November 7, with a total securities lending balance of 0, which is also above the 80th percentile level over the past year, suggesting a lack of short-selling activity [1] Company Overview - Beijing Spring Medical Equipment Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company was established on February 12, 1998, and went public on December 30, 2021, with a revenue composition of 99.89% from medical device products [2] - As of September 30, 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% year-on-year [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the company had 6,164 shareholders, an increase of 4.12% from the previous period, with an average of 46,906 circulating shares per shareholder, a decrease of 3.95% [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund, both of which are new entrants among the top ten circulating shareholders [3]

Investment Rating - The industry investment rating is maintained as "Outperform the Market" [2][57]. Core Insights - The orthopedic consumables sector has shown continuous improvement in performance during the first three quarters of 2025, with a positive trend in overseas expansion [3][10]. - The overall revenue of the orthopedic consumables sector increased by 17% year-on-year for Q1-Q3 2025, with net profit attributable to shareholders rising by 81% [5][10]. - The gross profit margin for the sector improved to 66% in Q1-Q3 2025, reflecting effective cost control and optimization [4][10]. - The trend of companies actively pursuing international markets is expected to become a significant growth driver [10][27]. Summary by Sections 1. Orthopedic Consumables Q3 2025 Report Analysis - The orthopedic consumables sector's revenue for Q1-Q3 2025 reached 49.18 billion, with a year-on-year growth of 17% [9]. - The gross profit margin for Q3 2025 was reported at 67%, an increase of 2.06 percentage points compared to the previous year [10]. - The net profit attributable to shareholders for Q3 2025 doubled year-on-year, indicating significant performance improvement [10]. 2. Segment Analysis - The joint business segment has seen stable growth due to the continuation of centralized procurement and an increase in both volume and price for leading companies [19][24]. - The spinal segment is experiencing a steady execution of centralized procurement, with leading domestic brands increasing their market share [25]. - The trend of domestic companies expanding overseas is gaining momentum, with a focus on product innovation and international development [27][29]. 3. Related Company Q3 Report Summary - Major companies in the sector, such as Dabo Medical, Weigao Orthopedics, and Spring Medical, have shown strong revenue growth and profitability improvements in Q3 2025 [12][41][45]. - Dabo Medical reported a revenue of 18.76 billion, up 22.69% year-on-year, with a net profit of 4.25 billion, reflecting a 77.03% increase [45]. - Spring Medical achieved a remarkable revenue growth of 109.5% in Q3 2025, turning a previous loss into a profit of 770.6 million [33].

Core Viewpoint - Spring Medical experienced a decline of 2.38% in stock price on November 7, with a trading volume of 83.6 million yuan and a total market capitalization of 10.21 billion yuan [1] Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its stock listed on December 30, 2021 [7] Product Portfolio - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][8] - The company has developed products such as hip and knee surgical robots and medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and China Europe Economic Selection Mixed A, both of which are new shareholders [9]

Core Viewpoint - Spring Medical has experienced a decline in stock price, with a cumulative drop of 7.83% over the past five days, closing at 26.62 yuan per share on November 7, 2023, with a total market capitalization of 10.211 billion yuan [1] Company Overview - Beijing Spring Medical Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021. The company specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal fixation systems [1] - The company's revenue composition is primarily from medical device products (99.89%), with a minor contribution from other sources (0.11%) [1] Fund Holdings - Rongtong Fund holds a significant position in Spring Medical, with its Rongtong Healthcare Industry Mixed A/B Fund (161616) owning 1,102,600 shares, representing 3.27% of the fund's net value, making it the tenth largest holding [2] - The fund has incurred a floating loss of approximately 716,700 yuan today and a total floating loss of 2,491,900 yuan during the five-day decline [2] Fund Manager Performance - The fund manager, Wan Minyuan, has a tenure of 9 years and 76 days, with a total fund size of 5.957 billion yuan, achieving a best return of 139.47% and a worst return of -21.98% during his tenure [3] - Co-manager Liu Xiyang has been in position for 1 year and 238 days, managing a fund size of 839 million yuan, with a best return of -3.58% and a worst return of -4.4% [3]

Core Viewpoint - Spring Medical experienced a stock price decline of 2.13% on November 7, with a current price of 26.69 CNY per share and a market capitalization of 10.237 billion CNY [1] Company Overview - Beijing Spring Lida Medical Devices Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021. The company specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. The products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [2] - The revenue composition is primarily from medical device products (99.89%) with a minor contribution from other sources (0.11%) [2] Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 755.6 million CNY, representing a year-on-year growth of 48.75%. The net profit attributable to the parent company was 192 million CNY, showing a significant increase of 213.21% year-on-year [2] - Since its A-share listing, the company has distributed a total of 359 million CNY in dividends, with 309 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average number of circulating shares per person decreased by 3.95% to 46,906 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which is the fourth-largest shareholder with 2.9585 million shares, and China Europe Economic Growth Mixed Fund A, which is the fifth-largest with 2.8326 million shares, both being new shareholders [3]

Group 1 - The core viewpoint of the report is that Guosen Securities has given Chuangli Medical (688236.SH, latest price: 27.11 yuan) an "outperform" rating due to strong revenue growth and better-than-expected net profit growth [1] - The company's net profit margin has significantly improved, while the sales expense ratio has decreased substantially [1] - Chuangli Medical is expanding its product line, and its overseas business is showing impressive growth [1]

Group 1 - The core viewpoint of the news is that Spring Medical experienced a slight decline in stock price while showing significant financing activity, indicating investor interest despite market fluctuations [1][2]. - On November 6, Spring Medical's stock fell by 1.09%, with a trading volume of 95.30 million yuan, and a net financing purchase of 3.67 million yuan [1]. - As of November 6, the total margin balance for Spring Medical was 48.20 million yuan, accounting for 0.61% of its market capitalization, which is above the 90th percentile of the past year [1]. Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of orthopedic medical devices, particularly joint prosthetics and spinal implants [2]. - The company reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, up 213.21% year-on-year [2]. - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2]. Group 3 - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan paid out in the last three years [3]. - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the fourth largest with 2.96 million shares, while two new shareholders, China Europe Economic Growth Mixed A and Ping An Low Carbon Economy Mixed A, are also noted [3].